Results 91 to 100 of about 1,772,507 (392)

Vaccine Myths: Setting the Record Straight [PDF]

open access: yes, 2018
Despite their standing as one of the most remarkable public health achievements, vaccines have been surrounded by dangerous myths since the development of the smallpox vaccine in the 18th century.
Boom, Julie A   +2 more
core   +1 more source

A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration [PDF]

open access: yes, 2014
Strategies to optimize responses to seasonal influenza vaccination in older adults include the use of adjuvants, higher antigen doses, and intradermal delivery.
Castellino, Flora   +9 more
core   +1 more source

Age‐Related Changes in Myeloid Cells and Their Impact on Subcutaneous Melanoma Growth in Mice

open access: yesAging and Cancer, EarlyView.
Our findings reveal that age‐related changes in subcutaneous melanoma growth and immunotherapy response are context‐dependent. In models where tumor growth and treatment resistance increase with age, this effect is partly driven by enhanced immunosuppression from myeloperoxidase‐active Gr‐1⁺ myeloid cells.
Kaitlyn M. Landreth   +7 more
wiley   +1 more source

Evaluation of the Induction of Immune Memory following Infant Immunisation with Serogroup C Neisseria meningitidis Conjugate Vaccines - Exploratory Analyses within a Randomised Controlled Trial [PDF]

open access: yes, 2014
Aim: We measured meningococcal serogroup C (MenC)-specific memory B-cell responses in infants by Enzyme-Linked Immunospot (ELISpot) following different MenC conjugate vaccine schedules to investigate the impact of priming on immune memory.
Birks, Jacqueline   +7 more
core   +5 more sources

Combination Ad26.RSV.preF/preF protein vaccine induces superior protective immunity compared with individual vaccine components in preclinical models

open access: yesnpj Vaccines, 2023
Respiratory syncytial virus (RSV) is a leading cause of severe respiratory disease for which no licensed vaccine is available. We have previously shown that a prefusion (preF) conformation-stabilized RSV F protein antigen and an adenoviral vector ...
Eirikur Saeland   +14 more
doaj   +1 more source

A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson

open access: yesHuman Vaccines & Immunotherapeutics, 2022
The novel coronavirus outbreak was declared a pandemic in March 2020. We are reviewing the COVID-19 vaccines authorized for use in the United States by discussing the mechanisms of action, administration, side effects, and efficacy of vaccines developed ...
Rikin Patel   +4 more
semanticscholar   +1 more source

Patient and Provider Perspectives on How Trust Influences Maternal Vaccine Acceptance Among Pregnant Women in Kenya [PDF]

open access: yes, 2019
Background Pregnant women and newborns are at high risk for infectious diseases. Altered immunity status during pregnancy and challenges fully vaccinating newborns contribute to this medical reality.
Adero, Maxwell   +14 more
core   +2 more sources

Analysis of pilot data assessing vaccine hesitancy in an urban clinic setting [PDF]

open access: yes, 2018
Widespread use of childhood vaccination has significantly reduced the burden of childhood disease, however a subset of parents are choosing to delay or refuse available vaccines.
Williams, Amelia
core  

Vaccines [PDF]

open access: yes, 2019
Since the introduction of smallpox vaccination more than two centuries ago, vaccines have been—and still are—instrumental in the prevention of infectious diseases. Nowadays vaccines form a heterogeneous group of pharmaceutical products that differ in several aspects from other biopharmaceuticals.
Jiskoot, Wim   +3 more
openaire   +2 more sources

Durability of Response to B‐Cell Maturation Antigen‐Directed mRNA Cell Therapy in Myasthenia Gravis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective We report the 12‐month follow‐up outcomes from a Phase 2 clinical trial (NCT04146051) evaluating Descartes‐08, a BCMA‐directed RNA chimeric antigen receptor T‐cell (rCAR‐T) therapy for refractory generalized myasthenia gravis (MG).
Nizar Chahin   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy